Monica Weldon Consulting, LLC

09/02/2026

Rare disease advocacy needs a new model.

I’m going to say something that may make some people uncomfortable:

It’s time to stop protecting organizations simply because they have been around for a long time.

The rare disease movement was built by pioneers who fought to make rare diseases visible, create incentives for drug development, establish patient registries, change FDA policy, and give families a voice.

We owe that generation an enormous debt.

But we cannot build the future using the architecture of the past.

The rare disease landscape has fundamentally changed.

Today we have patient-driven research, massive datasets, advanced biotechnology, gene and RNA therapies, AI, precision medicine, domestic biomanufacturing, new regulatory pathways, and an increasingly sophisticated understanding of how national security, supply chains, manufacturing and healthcare intersect.

Yet too much of rare disease advocacy is still organized around the same institutional structures, funding models and policy assumptions we developed decades ago.

That isn’t innovation. That’s institutional preservation.

The next generation of rare disease advocacy needs to be entrepreneurial, patient-driven, scientifically rigorous and unapologetically focused on outcomes.

We need organizations that can:

→ Build the research infrastructure themselves.
→ Turn patient data into usable scientific assets.
→ Connect patients directly with researchers and developers.
→ Create new economic incentives for rare-disease therapeutics.
→ Bring manufacturing back into the rare-disease conversation.
→ Use national security and industrial-base policy when appropriate.
→ Challenge regulatory barriers rather than simply working around them.
→ Build partnerships across government, industry, academia and patients.
→ Measure success by therapies developed and lives changed—not the number of meetings held.

And sometimes that means scrapping the model and building something new.

Not because the people who built the old system failed.

Because they succeeded—and the world moved on.

The next generation shouldn’t spend its energy defending yesterday’s institutions.

We should be building the institutions our children will need tomorrow.

I’ve spent more than a decade watching rare disease from the patient, research, policy and biotechnology sides.

I believe we are at an inflection point.

Rare disease doesn’t need another organization that simply asks for a seat at the table.

It needs organizations willing to build a new table.

The next era of rare disease advocacy should not be about preserving the movement.

It should be about reinventing it.

08/31/2026

President Trump’s new drug pricing announcement today deserves real credit — and real analysis.

Nine more pharmaceutical and biotech companies (including UCB, BridgeBio, and Sun Ten Pharmaceutical Co., Ltd.) just agreed to Medicaid pricing tied to the lowest rates charged anywhere in the world. This builds on the Most Favored Nation framework that’s already brought 17 of the largest drugmakers — roughly 86% of the branded drug market — into similar agreements. The White House reports prescription drug prices are down 3.9% since taking office, falling every month of 2026, with the VA alone locking in over $10 billion in pharmaceutical savings this fiscal year.

Congratulations to President Trump, HHS Secretary Kennedy Jr., Dr. Mehmet Öz, and the full team on this work.

Here’s the global context that makes this matter: U.S. prices across all drugs are nearly 2.78 times as high as prices in comparable OECD countries, and brand-name drug prices run at least 3.22 times higher. Some individual drugs show even starker gaps — certain inhalers used for chronic pulmonary disease cost over $120 per dose in the U.S. compared to roughly $1 in Canada and other countries. That gap isn’t sustainable, and it’s exactly what Most Favored Nation pricing is designed to close — by tying U.S. prices to the lowest price a manufacturer charges anywhere in the developed world.

This is a market-based fix, not a government-rationing one. In a capitalist system, price discipline doesn’t come from centralizing control — it comes from structuring incentives so competition does the work. That’s the fundamental flaw in single-payer “healthcare for all” models: they strip out the competitive pressure that drives prices down over time and replace it with a fixed system that can’t adapt or innovate at the same pace. You don’t fix a broken pricing system by removing the market from it. You fix it by making the market work better — more choice, more competition, more transparency, and international price parity.

This is a meaningful step in that direction.

The Trump administration has struck new drug pricing agreements with nine biotech and pharmaceutical companies including UCB SA, Bridgebio Pharma Inc. and Sun Pharmaceutical Industries Ltd.

08/13/2026

WE DID IT.

Less than a decade ago, there was nothing.

No clinical trials.

No therapeutic pipeline.

No roadmap.

No real infrastructure for SYNGAP1 research.

There were just families, unanswered questions, and children who deserved better.

I started this movement because I could not accept that my son—and the families who would come after us—would be left with nothing.

It took years of blood, sweat, tears, advocacy, research, fundraising, data collection, relationship-building, and refusing to take no for an answer.

And today, we have reached a moment I once could only dream about:

CAMP4 Therapeutics has received Australian regulatory and ethics clearance to begin its Phase 1/2 clinical trial of CMP-002, an investigational therapy for SYNGAP1-related disorder.

This is the first-in-human clinical trial of CMP-002.

Read that again.

From nothing to a therapeutic entering human clinical trials in less than a decade.

That didn’t happen by accident.

It happened because SYNGAP families built a movement. We collected data. We funded research. We connected scientists. We pushed industry. We educated policymakers. We made SYNGAP impossible to ignore.

I am incredibly proud of what we built together.

But I am even more proud of the families who kept showing up—through the setbacks, the grief, the uncertainty, and the years when there was no guarantee that any of this would ever become reality.

This is not the finish line.

It’s the beginning of a new chapter.

To every SYNGAP family who fought for their child when there was nothing to fight for:

Look how far we’ve come.

And to the scientists, clinicians, researchers, advocates, donors, industry partners, and families who helped turn an impossible dream into a clinical trial:

Thank you.

I started the movement.

We did it.

And I’m not done yet.

Planned first-in-human clinical trial to assess a disease modifying intervention for patients with SYNGAP1-related disorder Regulatory milestone enables...

08/11/2026

 Patients should never be an afterthought in biotechnology.

We should be at the table from the beginning—helping shape research priorities, clinical development, regulatory policy, access, and ultimately the therapies that can change lives.

That’s why I’m excited to see the patient advocacy community coming together for BIO’s Patient Advocacy Changemakers Event (PACE 2026) in Washington, D.C., October 22–23.

I’ve spent years on both sides of this conversation—as a rare disease parent and advocate, as someone who helped build a patient-driven research community, and as a policy professional working at the intersection of biotechnology, healthcare, national security, and innovation.

One thing has never changed:

The patient voice is not a “nice to have.” It is essential to getting innovation right.

For families living with rare and devastating diseases, we don’t have the luxury of waiting for the system to figure things out. We need researchers, biotech companies, policymakers, regulators, investors, and advocates working together—with patients helping drive the conversation.

The future of medicine depends on more than scientific breakthroughs.

It depends on whether we can translate those breakthroughs into real treatments, real access, and real hope for patients and families.

I’m looking forward to the conversations, connections, and opportunities to continue building a stronger bridge between patients, science, policy, and industry.

Because patients aren’t just the reason we innovate.

Patients are partners in innovation.

Register for the BIO Patient Advocacy Changemakers Event (PACE) and take advantage of our exclusive room block at The Mayflower Hotel in Washington, D.C.

08/10/2026

I’m incredibly grateful to the Building the Noise for giving me the opportunity to share my story.

There was a moment sitting in Texas Children’s Hospital when I was told what my son would never do. He had just been diagnosed with a rare genetic disorder, SYNGAP1, and as a mother, I was confronted with a future I didn’t understand and a system that didn’t have many answers.

I could have stayed in that place of helplessness.

Instead, I decided to become an advocate.

That decision took me places I never imagined—from building a global patient registry and driving research, to working with scientists, policymakers, federal agencies, and industry to change how we approach rare disease, biotechnology, and the needs of families.

My journey has never been about accepting what someone told me my son could or could not become. It has been about asking, “What if we refuse to accept the status quo?”

Thank you to the Advocacy Intel Network for allowing me to tell this story and for creating space for the voices of patients, caregivers, and advocates.

🎥 The full episode of Building the Noise premieres today, August 10, 2026.

Subscribe to the Advocacy Intel Network on YouTube and turn on notifications so you don’t miss it.

Sometimes, the greatest catalyst for action is being told that something is impossible.



https://open.spotify.com/episode/2GsNNrsp2PJtyx7JgCWZjp?si=6wk_dygXR-CEliTMP27skg
Monica Weldon Consulting, LLC

Building the Noise Podcast · Episode

07/22/2026

President Trump’s announcement that imported generic drugs will remain tariff-free until August 2028—followed by a 100% tariff and potentially 200% thereafter—creates a critical window to rebuild America’s pharmaceutical manufacturing base. (The Wall Street Journal⁠)

But tariffs alone will not solve the problem.

The rare disease community has already shown us what works when traditional market economics fail: targeted incentives, clear regulatory pathways, tax policy, market predictability, and public-private investment.

We should apply those same lessons to essential generic medicines.

Congress could create a National Priority Generic Drug designation within the Hatch-Waxman framework for medicines that are shortage-prone, primarily manufactured overseas, essential to military readiness, or critical during pandemics and CBRN emergencies.

That designation could provide:

• Tax credits for domestic API and finished-dose manufacturing
• Expedited FDA review and reduced regulatory fees
• Limited incentives for the first qualified U.S. manufacturer
• Long-term federal purchasing and stockpile commitments
• DPA, ASPR, and federal financing for advanced manufacturing facilities
• Procurement preferences based on quality, resilience, and domestic capacity—not simply the lowest price

Generic medicines account for approximately 90% of prescriptions filled in the United States, yet manufacturers operate on extremely narrow margins that often make building American facilities economically unrealistic.

The Orphan Drug Act helped transform rare disease development by recognizing that some markets require intentional government incentives. We now need that same level of policy creativity to protect America’s supply of essential medicines.

Tariffs can create urgency. Smart incentives, guaranteed demand, and sustainable reimbursement will create lasting domestic manufacturing.

This is how we bring critical generic medicines—and the jobs, technology, and security surrounding them—back to the United States.

The U.S. will place a 100% tariff on generic pharmaceuticals starting in August 2028, President Trump posted on social media Tuesday evening, saying he would give time for drugmakers to move facilities to the U.S. before imposing the levies. “Effective August 1st, 2026, all Generic Drugs being bro...

07/20/2026

🎙️ Stay tuned… my upcoming podcast interview is dropping soon!

What if the hardest chapter of your life was actually preparing you for your greatest purpose?

I never imagined that being the mother of a child with a rare genetic disorder would set me on a path from the classroom… to the boardroom… to the Pentagon.

When my son was diagnosed with , there was no roadmap. There was no established community. So we helped build one.

That journey transformed me from caregiver to advocate, researcher, strategist, and policy advisor.

Along the way, I went from earning degrees in biology and education to completing a Master of Science in Law, working at the intersection of science, business strategy, public policy, and national security. I’ve had the privilege of serving as a Governor Glenn Youngkin appointee to the Commonwealth Health Research Board, advising organizations on complex scientific and policy issues, working with a global law firm, and contributing to initiatives supporting our nation’s chemical and biological defense.

None of this was part of the original plan.

It has reinforced something I now believe deeply:

Your greatest adversity can become your greatest qualification.

I’m honored to sit down with Matt Toresco for an upcoming episode of Build the Noise with Monica Dudley-Weldon to share my journey—from special needs caregiver, to building one of the first organizations dedicated to SYNGAP1, to healthcare policy, national security, and the unexpected opportunities that continue to unfold.

We’ll talk about resilience, leadership, faith, innovation, and why saying “yes” to difficult seasons can open doors you never imagined.

And what lies ahead?

I don’t know exactly what God has planned, but I know this: I want to continue serving where science, innovation, policy, and national security intersect. Whether that’s helping shape the future of biomedical innovation, advancing technologies that protect our nation, mentoring future leaders, or serving our country in even greater capacities, I truly believe the biggest mission is still ahead.

Thank you, Matt, for the opportunity to share my story. I hope it reminds others that your past doesn’t define your future—it prepares you for it.

Stay tuned for the podcast release… I can’t wait to share this conversation with all of you.

06/29/2026

Today I officially completed my FEMA Federal Emergency Management Agency Community Emergency Response Team (CERT) training.

One thing this training reinforced is that preparedness isn’t something you think about only after a crisis—it begins long before one ever occurs.

Whether it’s a hurricane, flood, wildfire, severe storm, public health emergency, or another unexpected event, resilient communities are built by people who are willing to learn, prepare, and help one another when it matters most.

CERT training isn’t about replacing first responders. It’s about becoming a more informed, capable, and prepared citizen who can protect your family, support your neighbors, and assist your community until professional responders arrive.

In today’s world, emergencies can happen anywhere and often with little warning. Investing a little time in preparedness can make a tremendous difference when seconds matter.

I encourage everyone to consider taking a CERT course in your community. The knowledge, practical skills, and confidence you gain are valuable not only during disasters but in everyday life.

Preparedness isn’t about expecting the worst. It’s about being ready to help when others need it most.

https://training.fema.gov/is/courseoverview.aspx

PublicSafety Preparedness

06/04/2026

Biotechnology is no longer a future industry—it’s a national security, economic growth, and manufacturing imperative.

The U.S. Army’s newly announced biotechnology accelerator initiative signals something much bigger than a government program. It reflects a growing recognition that innovation, advanced computing, AI, biotechnology, and rapid commercialization must move faster and closer together to maintain America’s competitive advantage. The initiative aims to connect private industry, government, and high-performance computing resources to accelerate biotechnology and medical countermeasure development.

For business leaders, investors, manufacturers, and innovators, the message is clear: follow the signal.

The acceleration of biotechnology, advanced manufacturing, and resilient supply chains is creating unprecedented opportunities to bring critical capabilities and production back to the United States. Federal initiatives are increasingly focused on strengthening domestic biotechnology ecosystems, expanding advanced biomanufacturing, and building secure U.S.-based supply chains.

Congratulations to everyone involved in launching this important effort. Programs like these help bridge the gap between breakthrough innovation and real-world deployment while creating opportunities for startups, small businesses, non-traditional contractors, and established industry partners alike.

https://insidedefense.com/insider/army-establishing-technology-accelerator-biotechnology?0=ip_login_no_cache%3D2c00c1acc150ad12a90ab3a7b5c233b4

As Requests for Information (RFIs) and partnership opportunities continue to emerge, now is the time for organizations to engage, collaborate, and position themselves for growth.

If your company is exploring biotechnology, advanced manufacturing, government partnerships, innovation strategy, or federal opportunities and needs support navigating the landscape, feel free to reach out. I’m always happy to discuss how I can help.

05/26/2026

Pandemic preparedness is no longer just a healthcare conversation — it’s a national security, economic resilience, and technology conversation.

I recently wrote about the growing importance of vaccines, biotechnology, AI-powered biosurveillance, and rare-disease innovation in preparing for future biological threats such as Ebola and hantavirus outbreaks.

One area I focused on is the FDA’s Commissioner’s National Priority Voucher Program — an important step forward in accelerating innovation tied to urgent national priorities. During my work supporting the defense industrial base, I advocated for stronger national-priority pathways designed to help accelerate technologies connected to preparedness, health security, and national defense.

The future of biodefense will depend on how quickly government, biotech, pharmaceutical companies, and emerging technologies can work together before crises escalate.

This is not just about treatment anymore.

It’s about prediction, prevention, resilience, and building systems capable of responding faster than the next outbreak spreads.

Read the full blog here: https://www.monicaweldonconsulting.com/blog/americas-next-defense-frontier-viruses-vaccines-ai-and-the-race-to-prevent-the-next-global-crisis


CPE for Chemical, Biological, Radiological and Nuclear Defense

Explore how AI, biotechnology, vaccine innovation, and rare disease research are reshaping pandemic preparedness and national defense. Discover the future of global health security, outbreak prevention, and biotech innovation in a rapidly changing world.